Brief: Sinopharm Group Says HY Revenue RMB300.95 Bln
Aug 28 (Reuters) - Sinopharm Group Co Ltd 1099.HK :
* HY REVENUE RMB300.95 BILLION VERSUS RMB261.5 BILLION
* HY PROFIT ATTRIBUTABLE RMB4.10 BILLION VERSUS RMB3.69
BILLION
* NO INTERIM DIVIDEND WAS PROPOSED FOR SIX-MONTH PERIOD
ENDED 30
JUNE 2023
Source text for Eikon: ID:nHKS3Qvpdk
Further company coverage: 1099.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For